Showing results (11-20 of 187) with videos related to
Sort By:
Pageof 19
Bailliere'S Best Practice & Research. Clinical Endocrinology & Metabolism|July 26, 2000
Growth hormone receptor antagonists therapy for acromegalyC Parkinson, P J TrainerExpert Opinion on Investigational Drugs|January 5, 2002
The place of pegvisomant in the management of acromegalyC Parkinson, P J TrainerExperimental Physiology|July 12, 2008
Growth hormone excess and the development of growth hormone receptor antagonistsC E Higham, P J TrainerClinical Endocrinology|September 1, 1995
The effect of an opiate antagonist on the hormonal changes induced by hexarelinM Korbonits, P J Trainer, G M BesserDiabetic Medicine : a Journal of the British Diabetic Association|September 2, 2009
Stabilizing effect of exenatide in a patient with C-peptide-negative diabetes mellitusA N Paisley, M W Savage, P G WilesThe Journal of Clinical Endocrinology and Metabolism|November 10, 2001
The relationship between serum GH and serum IGF-I in acromegaly is gender-specificC Parkinson, W D Ryder, P J Trainer, et al.Advanced Drug Delivery Reviews|September 23, 2003
Pegvisomant in the treatment of acromegalyC Parkinson, J A Scarlett, P J TrainerHormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme|September 19, 2006
Effect of growth hormone in an experimental model of protein hypercatabolism induced by glucocorticoidsA Cantón, P J Trainer, E Martinez-Cáceres, et al.Clinical Endocrinology|April 28, 2011
Serum regulates cortisol bioactivity by corticosteroid-binding globulin-dependent and independent mechanisms, as revealed by combined bioassay and physicochemical assay approachesI Perogamvros, M Kayahara, P J Trainer, et al.The Journal of Clinical Endocrinology and Metabolism|August 6, 2010
Salivary cortisone is a potential biomarker for serum free cortisolI Perogamvros, B G Keevil, D W Ray, et al.Pageof 19